Low Estrogen Symptoms in Women: What Could Be Causing Them

Why Estrogen Matters and What Happens When Levels Fall

Estrogen is not a single hormone. It is a family of three steroid hormones (estradiol, estrone, and estriol) that regulate reproductive function, bone metabolism, cardiovascular protection, and central nervous system signaling in women. When circulating estradiol drops below physiologic thresholds, the effects reach far beyond the reproductive tract.

The clinical picture of estrogen deficiency typically includes vasomotor symptoms (hot flashes, night sweats), vaginal dryness, sleep disruption, mood changes, and accelerated bone loss. A 2015 analysis published in Menopause found that 80% of perimenopausal and postmenopausal women experience vasomotor symptoms, with a median duration of 7.4 years [1]. That number is not trivial. It means the majority of women will live through years of symptoms driven by declining estradiol.

Bone health deteriorates quickly once estrogen withdrawal begins. Data from the Study of Women's Health Across the Nation (SWAN) demonstrated that women lose an average of 2.5% of lumbar spine bone mineral density per year during the menopause transition, with the steepest losses occurring in the two years surrounding the final menstrual period [2]. This rate is roughly six times faster than the premenopausal baseline.

Cardiovascular risk also shifts. Estradiol promotes endothelial nitric oxide production and favorable lipid profiles. The Framingham Heart Study showed that women who underwent natural menopause before age 40 had a 2.0-fold increased risk of coronary heart disease compared to women who reached menopause at the median age [3].

The question is not whether low estrogen causes symptoms. It does. The real clinical question is why estrogen levels have dropped.

Perimenopause and Menopause: The Most Common Cause

For most women, declining estrogen is a normal part of reproductive aging. The median age of natural menopause in the United States is 51.4 years, but the hormonal shift begins years earlier during perimenopause, which can start as early as the late 30s.

During perimenopause, ovarian follicle counts decrease and the remaining follicles become less responsive to follicle-stimulating hormone (FSH). Estradiol production becomes erratic rather than simply declining. One cycle might produce supraphysiologic estradiol levels; the next might produce very little. This variability explains why perimenopausal women often describe symptoms that come and go unpredictably.

The Stages of Reproductive Aging Workshop (STRAW+10) criteria, published in Climacteric in 2012, define the menopause transition by changes in menstrual cycle length and elevated FSH [4]. Late perimenopause is characterized by skipped cycles of 60 days or more. Postmenopause is confirmed after 12 consecutive months without a menstrual period.

Dr. Stephanie Faubion, Medical Director of The Menopause Society, has stated: "Menopause is not a disease. It is a natural biological process. But the symptoms it causes are real and can significantly affect quality of life" [5].

Ethnicity and body composition influence the experience. SWAN data showed that Black women report vasomotor symptoms for a median of 10.1 years, compared to 6.5 years for white women and 5.4 years for Japanese women [1]. Body mass index, smoking status, and stress exposure all modify symptom severity. These are not minor modifiers. They can mean the difference between tolerable discomfort and years of disrupted sleep.

Primary Ovarian Insufficiency

Primary ovarian insufficiency (POI), previously called premature ovarian failure, affects approximately 1% of women before age 40 and 0.1% before age 30 [6]. It is not early menopause. Many women with POI retain intermittent ovarian function.

The condition is defined by oligo- or amenorrhea for four or more months combined with two serum FSH levels above 25 mIU/mL, drawn at least four weeks apart, in a woman younger than 40 [6]. The etiology is identifiable in only about 10 to 25% of cases. Known causes include:

Genetic factors. Turner syndrome (45,X karyotype) and FMR1 premutations are the most common genetic associations. Women carrying FMR1 premutations (55 to 200 CGG repeats) have a 20% lifetime risk of POI, compared to roughly 1% in the general population [7].

Autoimmune disease. Up to 20% of POI cases involve autoimmune oophoritis, often coexisting with autoimmune thyroid disease or adrenal insufficiency [6]. Screening for thyroid antibodies and adrenal antibodies is standard practice in the workup.

Iatrogenic causes. Chemotherapy (particularly alkylating agents like cyclophosphamide) and pelvic radiation cause dose-dependent ovarian damage. Gonadotoxic chemotherapy can induce POI in 40 to 80% of premenopausal women, depending on the agent, cumulative dose, and patient age at treatment [8].

The 2024 European Society of Human Reproduction and Embryology (ESHRE) guideline recommends hormone replacement therapy in women with POI at least until the average age of natural menopause (51 years) to mitigate bone, cardiovascular, and neurological consequences of prolonged estrogen deficiency [6]. This is not optional risk reduction. It is standard care.

Hypothalamic Amenorrhea: When the Brain Shuts Down the Signal

Functional hypothalamic amenorrhea (FHA) is an underdiagnosed cause of low estrogen in premenopausal women. It occurs when the hypothalamus reduces or stops pulsatile secretion of gonadotropin-releasing hormone (GnRH), which in turn suppresses FSH, LH, and ovarian estradiol production.

Three overlapping triggers drive FHA: energy deficit, excessive exercise, and psychological stress. These triggers do not require extremes. A woman does not need an eating disorder diagnosis to develop FHA. A persistent caloric deficit of 300 to 500 kcal/day, combined with moderate exercise stress, can suppress the hypothalamic-pituitary-ovarian axis within months [9].

The Endocrine Society's 2017 clinical practice guideline defines FHA as amenorrhea for three or more months with low or normal gonadotropins (FSH and LH typically both <10 mIU/mL) in the absence of organic pathology [9]. Lab values distinguish FHA from POI: in FHA, FSH is low-normal; in POI, FSH is elevated. This distinction matters because the treatment is completely different.

The Female Athlete Triad (now expanded to Relative Energy Deficiency in Sport, or RED-S) represents the exercise-related end of this spectrum. A 2014 consensus statement by the International Olympic Committee estimated that RED-S affects up to 50% of elite female athletes in lean-build sports [10]. Bone stress fractures, menstrual irregularity, and low estradiol are the hallmark consequences.

Treatment centers on resolving the energy deficit. The Endocrine Society guideline explicitly recommends against oral contraceptives as a substitute for addressing the root cause, because exogenous ethinyl estradiol masks the underlying dysfunction without restoring hypothalamic signaling [9]. Weight restoration of as little as 2 to 3 kg has been shown to resume menses in some cases.

Medications and Medical Treatments That Lower Estrogen

Several categories of medications directly suppress estrogen production or activity. Recognizing these is critical because the low estrogen is intentional and iatrogenic, not a mystery requiring workup.

Aromatase inhibitors (letrozole, anastrozole, exemestane) block the conversion of androgens to estrogen. They are first-line adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. The ATAC trial (N=9,366) demonstrated that anastrozole reduced breast cancer recurrence by 26% compared to tamoxifen at a median follow-up of 68 months, but musculoskeletal symptoms and bone loss were significantly more common in the anastrozole group [11].

GnRH agonists and antagonists (leuprolide, elagolix, relugolix) suppress pituitary gonadotropin release. Elagolix, approved for endometriosis-associated pain, reduced estradiol to postmenopausal levels (mean 12.3 pg/mL at the 200 mg twice-daily dose) in the Elaris EM-I and EM-II trials [12]. Women on these agents experience menopausal symptoms by design.

Bilateral oophorectomy causes immediate, permanent estrogen deprivation. Unlike natural menopause, there is no gradual transition. The Mayo Clinic Cohort Study of Oophorectomy and Aging found that women who underwent bilateral oophorectomy before age 45 without estrogen replacement had increased all-cause mortality (hazard ratio 1.67 to 95% CI 1.16 to 2.40) [13].

Chemotherapy and pelvic radiation damage ovarian tissue directly. Alkylating agents are the most gonadotoxic class. The degree of ovarian damage correlates with cumulative dose and patient age, with women over 35 at greatest risk of permanent ovarian failure after treatment [8].

How Low Estrogen Is Diagnosed

Diagnosis combines clinical assessment with targeted laboratory testing. No single lab value confirms estrogen deficiency in every context, because normal ranges depend heavily on menstrual cycle phase, age, and menopausal status.

Serum estradiol (E2) is the primary marker. In premenopausal women, estradiol fluctuates from approximately 30 pg/mL in the early follicular phase to 200 to 400 pg/mL at the midcycle peak. A consistently low estradiol (<30 pg/mL) on early follicular or random sampling suggests clinically significant deficiency. In postmenopausal women, estradiol typically falls below 20 pg/mL [14].

FSH helps determine the cause. Elevated FSH (above 25 to 30 mIU/mL) indicates ovarian failure, whether from menopause or POI. Low-normal FSH (<10 mIU/mL) with low estradiol points toward a hypothalamic or pituitary cause [9].

Additional labs depend on the clinical picture:

• Anti-Mullerian hormone (AMH) reflects ovarian reserve. Very low AMH (<0.3 ng/mL) supports a diagnosis of diminished ovarian reserve or POI [6].
• Thyroid function tests (TSH, free T4) to rule out thyroid disease mimicking or contributing to menstrual irregularity.
• Prolactin to exclude prolactinoma.
• Karyotype in women with POI before age 30 (to evaluate for Turner syndrome mosaicism).
• FMR1 premutation testing in women with unexplained POI.

The 2022 Menopause Society position statement clarifies that FSH testing is unnecessary for diagnosing menopause in women over 45 with typical vasomotor symptoms and amenorrhea [5]. Clinical diagnosis is sufficient. Testing adds value primarily in younger women where the differential includes POI and FHA.

DEXA scanning should be considered in any woman with prolonged estrogen deficiency. The World Health Organization defines osteoporosis as a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip [2]. Women with POI or prolonged amenorrhea from any cause should have baseline bone density assessment regardless of age.

Treatment Options Based on the Underlying Cause

Treatment for low estrogen is not one-size-fits-all. The right approach depends on why estrogen is low, the woman's age, her reproductive goals, and her risk profile.

For menopausal and perimenopausal women, systemic hormone therapy (HT) remains the most effective treatment for vasomotor symptoms. The 2022 Menopause Society position statement recommends initiating HT in symptomatic women under age 60 or within 10 years of menopause onset, provided there are no contraindications [5]. Options include transdermal estradiol (patches delivering 0.025 to 0.1 mg/day), oral estradiol (0.5 to 2 mg/day), or conjugated equine estrogens. Women with an intact uterus require progestogen co-administration to prevent endometrial hyperplasia.

The Women's Health Initiative (WHI) initially raised concerns about HT safety, but subsequent reanalysis clarified the age-dependent risk profile. Among women aged 50 to 59, estrogen-alone therapy was associated with reduced coronary heart disease risk (hazard ratio 0.63 to 95% CI 0.36 to 1.09) and no increase in breast cancer incidence over 7.2 years of follow-up [15]. The risk-benefit calculation is favorable for younger symptomatic women.

For POI, the ESHRE guideline recommends physiologic estrogen replacement, not low-dose menopausal HT [6]. Target doses are higher: transdermal estradiol 100 mcg/day or oral estradiol 2 mg/day, approximating what healthy ovaries would produce. Bone health, cardiovascular protection, and sexual function all improve with adequate replacement.

Dr. Nanette Santoro, Professor of Obstetrics and Gynecology at the University of Colorado School of Medicine, has noted: "Women with POI are not the same as postmenopausal women. They need full physiologic replacement, and they need it until at least age 51" [6].

For hypothalamic amenorrhea, the primary treatment is addressing the underlying energy deficit. Nutritional rehabilitation, stress management, and reduction in exercise intensity are the cornerstones. Estrogen replacement may be used temporarily to protect bone density while recovery is underway, but it should not replace behavioral intervention [9].

For medication-induced estrogen suppression, the approach depends on the clinical context. Women on aromatase inhibitors for breast cancer require bone-protective strategies (bisphosphonates or denosumab, calcium, vitamin D, weight-bearing exercise) rather than estrogen add-back, because estrogen would counteract the therapeutic intent [11].

When to See a Doctor

Not every instance of fatigue, mood change, or irregular periods is caused by low estrogen. But certain patterns warrant evaluation. Seek medical assessment if you experience missed periods for three or more consecutive months when not pregnant, hot flashes or night sweats that disrupt sleep, vaginal dryness causing pain with intercourse, or a bone stress fracture with minimal trauma.

Women under 40 with menstrual irregularity deserve particular attention. POI is missed or delayed in diagnosis by an average of 2.1 years according to a 2019 European survey of affected women [6]. Earlier recognition leads to earlier treatment and better long-term bone and cardiovascular outcomes.

A single blood draw on a random day is often insufficient. Request morning labs drawn between cycle days 2 and 5 (if still cycling) for the most interpretable results. If periods have stopped entirely, testing can be done on any day. Ask for estradiol, FSH, TSH, and prolactin at minimum. AMH adds value in women concerned about fertility.

The starting daily dose of transdermal estradiol for symptomatic postmenopausal women is 0.025 to 0.05 mg/day, titrated based on symptom response at 4 to 8 week intervals [5].